Azactam


Also found in: Dictionary, Medical, Wikipedia.
  • noun

Synonyms for Azactam

an antibiotic (trade name Azactam) used against severe infections

References in periodicals archive ?
In the ABSSSI trials, 1,396 adult patients received Teflaro or Vancocin plus Azactam.
Revenue for Azactam and Maxipime for the first quarter of 2010 was $25.
The decrease in revenue from the BioNeurology business was due to the cessation of revenue from Maxipime, Azactam and Prialt, offset by increased revenue from Tysabri.
Elan ceased distributing Azactam as of March 31, 2010 and will not earn any future revenues from this product.
The increase in revenues from the BioNeurology business was driven by Tysabri, which more than offset the expected reduced revenues from Azactam and Prialt.
For the full-year 2009, revenue from Azactam decreased 16% to $81.
Maxipime and Azactam will be co-promoted by over 500 Bristol-Myers Squibb representatives for the remainder of 1999.
The increased gross margin was driven by the 30% increase in sales of Tysabri and the Fampridine-SR license fee, which more than offset the loss of gross margin as a result of reduced sales of Azactam and Maxipime.
We are also very excited to be marketing our new hospital products, Maxipime and Azactam, through our co-promotion agreement with Bristol-Myers Squibb Company," noted Mr.
The increased gross margin was driven by significantly higher sales of Tysabri, which more than offset the loss of gross margin as a result of reduced sales of Azactam, Maxipime and revenues from EDT.
For the full-year 2008, revenue from Azactam increased 12% to $96.
Although total revenue increased by 53%, selling, general and administrative (SG&A) expenses declined by 6%, reflecting reduced sales and marketing costs and amortization expense relating to Maxipime and Azactam, and the operating leverage associated with Tysabri.
is appointed the exclusive distributor for Maxipime (cefepime HCl) and Azactam (aztreonam) in the United States.
Although revenue increased by 30%, selling, general and administrative (SG&A) expenses declined by 15%, reflecting reduced sales and marketing costs and amortization expense relating to Maxipime and Azactam, and the operating leverage associated with Tysabri.
These include the anti-cancer drug TAXOL, anti-infective drugs, Cefzil and Azactam and a range of cardiovascular products.